INTRODUCTION
============

Acute kidney injury (AKI) is a serious condition \[[@gfy294-B1]\] with established risk factors \[age, chronic kidney disease (CKD) and vascular comorbidities\] \[[@gfy294-B2]\]. It is associatied with increased long- term renal replacement therapy (RRT) \[[@gfy294-B3]\], mortality \[[@gfy294-B4]\] and CKD progression even when post-AKI kidney function returns to 'normal' \[[@gfy294-B5]\]. However, most publications focus on hospitalized patients cared for by generalists. There are limited data regarding the impact of episodes of AKI among people already under the care of nephrologists \[[@gfy294-B6]\]. Those under the regular care of nephrologists are a prioritized group, often with a known underlying renal diagnosis. They may undergo more frequent blood tests, which may increase the likelihood of finding incidental changes in serum creatinine (i.e. not prompted by clinical condition) or non-meaningful changes in creatinine (false-positive AKI episodes) \[[@gfy294-B7]\].

Clinical evidence is important for guiding clinical decisions both directly (risk prediction tools \[[@gfy294-B8]\]) and indirectly (informing clinical guidelines \[[@gfy294-B2]\]). Risk tools, such as the kidney failure risk equation (KFRE), can be helpful adjuncts for triaging patients and reducing waiting times \[[@gfy294-B11]\]. However, clinicians should be mindful that evidence generated from one context (people in an unselected population) may not be generalizable to others (selected people already in nephrology clinics) \[[@gfy294-B12]\]. It is therefore important to understand the prognostic implications of small changes in creatinine that occur among people under nephrology clinic care and whether these implications vary according to underlying renal diagnosis, age or other parameters. It is also unclear if, in the setting of recent AKI, prognosis can still be adequately described by established decision tools \[[@gfy294-B8]\] or if previous episodes of AKI should be factored in, particularly when deciding if someone with recent AKI but otherwise preserved kidney function should receive ongoing clinic care \[[@gfy294-B13]\].

The purpose of this analysis was to evaluate the impact of small changes in serum creatinine (AKI episodes according to established definitions) on the long-term outcomes of those already under the care of nephrologists. First, we determined whether AKI was independently associated with kidney failure or death (a competing risk) in this population. Then we evaluated the incremental improvement of adding AKI to established predictors in the KFRE for predicting kidney failure among those already under nephrology care.

MATERIALS AND METHODS
=====================

Population
----------

The Patient Records and Outcome Management Information System (PROMIS) collects health data from all people with kidney disease who receive care from a nephrologist in a kidney care clinic in any of 41 renal units in British Columbia (population ∼4.5 million) \[[@gfy294-B14]\]. People receive tests with protocolized regularity with minimum blood test frequencies in accordance with international guidelines \[[@gfy294-B15]\]. This unique province-wide dataset allows insight into the prognosis of people directly cared for by nephrologists. For these people, the dataset includes blood tests both from clinic visits and hospitalizations. For this analysis, the population comprised people \>18 years of age who entered follow-up in PROMIS from 1 January 2003 to 31 July 2009 and who remained alive after a 2-year observation period without need for long-term RRT or estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m^2^. The study was approved by the Providence Health Care Research Ethics Board.

Exposure
--------

The exposure was an episode of AKI during 2 years of initial observation from the date of first entry into PROMIS. The comparator was no AKI episode. We used a Kidney Disease: Improving Global Outcomes (KDIGO)-based definition for AKI incorporating a hierarchy of serum creatinine changes. This definition for AKI has previously been described in detail elsewhere \[[@gfy294-B4]\]. Briefly, the definition involves one of three criteria: (i) serum creatinine ≥1.5 times higher than the median of all creatinine values 8--90 days ago or 91--365 days ago if no tests between 8 and 90 days; (ii) serum creatinine ≥1.5 times higher than the lowest creatinine within 7 days and (iii) serum creatinine \>26 µmol/L higher than the lowest creatinine within 48 h.

Outcomes
--------

Subsequent outcomes were kidney failure and death without kidney failure. Kidney failure was defined as either long-term RRT or an eGFR \<15 mL/min/1.73 m^2^ sustained for at least 90 days \[[@gfy294-B15]\]. For eGFR we used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation \[[@gfy294-B16]\].

Follow-up
---------

To avoid immortal time bias, follow-up started at the end of a 2-year observation period (illustrated in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S1](#sup1){ref-type="supplementary-material"}). Follow-up continued until the first outcome or for a further 5 years (i.e. up to July 2016).

Covariates
----------

Covariates were age, sex and eGFR at baseline and after the 2-year observation period, proteinuria, blood pressure (systolic and diastolic), history of diabetes mellitus and primary renal diagnosis as recorded at baseline in the PROMIS database. Proteinuria was determined using urine albumin/creatinine measurements \[[@gfy294-B15]\].

Statistical analyses
--------------------

We reported the number of people who developed AKI by each of the three main definition critera, by AKI severity stage and by the presence of recurrent episodes. We compared the characteristics of people with and without AKI during the 2-year observation period and determined the proportion of people with kidney failure, death without kidney failure (competing risk) or alive without kidney failure after 5 years of follow-up (i.e. 7 years from the date of entry into PROMIS). For clarity of presentation in the characteristics tables, proteinuria was grouped as severe, moderate, none/mild and unrecorded (albumin:creatinine ratio \>300, 30--300, \<30 mg/g and unrecorded, respectively) and eGFR was grouped with CKD stage groups based on KDIGO CKD criteria \[[@gfy294-B15]\]. Both covariates were analysed continuously in the prediction models.

For those with and without AKI, we plotted cumulative incidence functions for kidney failure stratified by age, eGFR and underlying renal diagnosis (recognized predictors of kidney failure) \[[@gfy294-B9]\]. We fitted Cox models for the cause-specific hazard ratio (HR) (AKI versus no AKI) for kidney failure and the competing risk of death without kidney failure adjusted for covariates. Continuous variables were assessed for non-linearity visually and using fractional polynomials \[[@gfy294-B17]\]. The proportional hazards assumption was verified by −ln{−ln(survival)} plots.

As kidney failure is potentially a rare endpoint, in a sensitivity analysis we used a recognized alternative endpoint: 30% sustained decrease in eGFR or long-term RRT \[[@gfy294-B18]\]. In addition, as both competing outcomes may vary by AKI phenotype, in subgroup analyses we limited our definition of AKI to the third criterion (small changes of serum creatinine \>26 µmol/L in 48 h), to only those with AKI severity stage 1 (stages 2 and 3 excluded) and to only those with recurrent AKI episodes during the 2-year observation period.

For prediction models of 5-year kidney failure risk we externally validated the widely used 5-year KFRE \[[@gfy294-B8], [@gfy294-B9]\] in the nephrology clinic cohort and compared its performance with two refitted models developed in the same cohort. For one refitted model we used the same variables as the four-variable KFRE (age, sex, eGFR and albumin:creatinine ratio) and in the second we added AKI as an additional variable. As death is a competing risk for kidney failure, competing risks regression models were constructed using the Fine and Gray technique \[[@gfy294-B19]\]. The association of AKI (versus no AKI) with poor outcomes is greater at higher eGFRs \[[@gfy294-B4], [@gfy294-B5]\], and people with an eGFR \<30 mL/min/1.73 m^2^ typically receive regular nephrology clinic care (per current guidelines) \[[@gfy294-B15]\] for complications of CKD even if kidney failure risk is low. Therefore our analyses were stratified by eGFR (\</≥30 mL/min/1.73 m^2^) and prediction models assessing incremental improvement in AKI focused on those with eGFR ≥30 mL/min/1.73 m^2^.

To assess model performance we compared discrimination of these models by calculating the area under the receiver operated characteristics curve (AUC). The value of an AUC lies between 0.5 and 1, with 0.5 indicating no better than a coin toss and 1 indicating perfect discrimination between those with and without an outcome \[[@gfy294-B20]\]. We also evaluated calibration by plotting the mean observed proportion of people with the outcomes against the predicted probabilities of the outcome by increasing tenths of predicted probabilities. Further, for the external validation of KFRE we calculated the calibration slope. This is the coefficient of a regression model containing the linear predictor of the KFRE \[[@gfy294-B21]\]. A slope close to 1 indicates excellent agreement, whereas a slope \<1 may indicate unduly extreme predictions and a slope \>1 may indicate predictions that do not vary sufficiently for that model \[[@gfy294-B22], [@gfy294-B23]\].

Even if a model discriminates well overall, this may not lead to better decisions about the appropriate threshold needed for clinical use. For instance, a new model may be useful at a risk threshold cut-off of 80%, but if intervention is recommended when the risk of an outcome is lower (e.g. 10%), the same model may no longer be useful \[[@gfy294-B24]\]. Decision curve analysis is a method of assessing the clinical usefulness of different models at an appropriate (preferably prespecified) threshold compared with strategies of 'treat all' or 'treat none' \[[@gfy294-B25]\]. It is a plot of the 'net benefit' of each model, which is a trade-off between true positives and false positives at different thresholds described by the equation below \[[@gfy294-B25]\]. 'Treatment' could be a new drug, a procedure or a decision to follow-up. $$Net~benefit = \left( \frac{true~positive}{total~sample~size} \right) - ~\left\lbrack {\left\lbrack \frac{false~positive}{total~sample~size} \right\rbrack~ \times \left\lbrack \frac{threshold~probability}{1 - threshold~probability} \right\rbrack} \right\rbrack$$

Elsewhere, a 5-year KFRE risk threshold ≥3% has been suggested and used as a criterion for eligible transition from primary care to nephrology care among people with an eGFR ≥30 mL/min/1.73 m^2^ \[[@gfy294-B11]\]. Decision curve analysis should therefore show a net benefit at this threshold. Analyses were performed in Stata SE 13 (StataCorp, College Station, TX, USA) \[[@gfy294-B26]\].

RESULTS
=======

Population
----------

From a population of ∼4.5 million, there were 9531 people who were registered into a nephrologist's care in PROMIS between 1 January 2003 and 31 July 2009, including 8726 who were still alive after 2 years of observation. As shown in [Figure 1](#gfy294-F1){ref-type="fig"}, after excluding those who were already receiving long-term RRT or had an eGFR \<15 mL/min/1.73 m^2^, 7491 people met the study inclusion criteria, including 995 (13.3%) with an episode of AKI. Subsequent follow-up was for a median of 5 years, or 27 742 patient-years. A breakdown of AKI by definition criteria, severity stage and recurrence of AKI episodes is provided in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}.

![Development of the study population.](gfy294f1){#gfy294-F1}

Baseline characteristics of people with and without AKI
-------------------------------------------------------

Table [1](#gfy294-T1){ref-type="table"} describes the characteristics of people with and without an episode of AKI during the initial 2-year observation period prior to study follow-up. The proportion of people with AKI was no greater among older patients than younger patients and no different for women and men. In this cohort, AKI episodes occurred more frequently among those with baseline eGFR ≥60 versus \<30 mL/min/1.73 m^2^ (18.8% versus 13.2%). There were also more AKI episodes among people with severe proteinuria and high blood pressure. Occurrence of AKI varied by underlying renal diagnosis (from 4.4% of people with polycystic kidney disease to 17.0% of people with diabetes-related kidney disease).

###### 

Characteristics of people with and without AKI during the 2-year observation period

                                     Overall, *N*      AKI in first 2  years   No AKI in first 2  years         
  --------------------------------- -------------- -- ----------------------- -------------------------- ------ ------
  *N*                                    7491                   995                                       6496  
  Age (years)                                                                                                   
   ≥80                                   1488                   162                      16.3             1326   20.4
   60--79                                4365                   617                      62.0             3748   57.7
   \<60                                  1638                   216                      21.7             1422   21.9
  Sex                                                                                                           
   Female                                3451                   531                      53.4             3509   54.0
   Male                                  4040                   464                      46.6             2987   46.0
  Baseline eGFR (mL/min/1.73 m^2^                                                                               
   \<30                                  2672                   352                      35.4             2320   35.7
   30--44                                2954                   367                      36.9             2587   39.8
   45--59                                1142                   140                      14.1             1002   15.4
   ≥60                                   723                    136                      13.7             587    9.0
  Baseline proteinuria                                                                                          
   Severe                                1415                   229                      23.0             1186   18.3
   Moderate                              1873                   271                      27.2             1602   24.7
   None/mild                             1570                   207                      20.8             1363   21.0
   Not tested                            2633                   288                      28.9             2345   36.1
  Systolic blood pressure (mmHg                                                                                 
   ≥160                                  911                    134                      13.5             777    12.0
   120--160                              3603                   487                      48.9             3116   48.0
   \<120                                 1235                   177                      17.8             1058   16.3
   Not recorded                          1742                   197                      19.8             1545   23.8
  Diastolic blood pressure (mmHg                                                                                
   ≥100                                  148                    24                       2.4              124    1.9
   60--100                               5014                   687                      69.0             4327   66.6
   \<60                                  587                    87                       8.7              500    7.7
   Not recorded                          1742                   197                      19.8             1545   23.8
  Diabetes mellitus                                                                                             
   Yes                                   4511                   707                      71.1             3804   58.6
   No                                    2980                   288                      28.9             2692   41.4
  Primary renal diagnosis                                                                                       
   Diabetes mellitus                     1220                   207                      20.8             1013   15.6
   Glomerulonephritis                    368                    44                       4.4              324    5.0
   Interstitial/intrinsic renal          699                    101                      10.2             598    9.2
   Multisystem disorder                  430                    67                       6.7              363    5.6
   Polycystic kidney disease             159                     7                       0.7              152    2.3
   Vascular/hypertension                 1636                   225                      22.6             1411   21.7
   Uncertain aetiology                   1059                   134                      13.5             925    14.2
   Not recorded                          1920                   210                      21.1             1710   26.3
  Year of first follow-up                                                                                       
   2003--06                              3139                   440                      44.2             2699   41.5
   2007--09                              4352                   555                      55.8             3797   58.5

All people in this analysis were observed for 2** **years for the development of AKI. Baseline refers to covariate values at the beginning of a 2-year observation period prior to study follow- up.

Overall 5-year outcomes among people with and without AKI
---------------------------------------------------------

Five-year outcomes are reported in [Table 2](#gfy294-T2){ref-type="table"}, stratified by age, sex, eGFR and other characteristics. Overall, people with AKI in the preceding 2 years (versus no AKI) had an increased risk of kidney failure (33.1% versus 26.3%) and the competing outcome of death (23.8% versus 16.8%) (χ^2^ P \< 0.001; [Table 2](#gfy294-T2){ref-type="table"}). This pattern was present irrespective of age, sex, eGFR (as measured after the 2-year observation period), proteinuria and renal diagnosis.

###### 

Subsequent 5-year outcomes among people with and without an episode of AKI in the previous 2-year observation period

                                                                                        AKI in previous 2 years   No AKI in previous 2 years                                     
  ----------------------------------------------------------------------------- ------ ------------------------- ---------------------------- ------ ------ ------ ------ ------ ------
  *N*                                                                            7491             995                        43.1              33.1   23.8   6496   56.9   26.3   16.8
  Age (years                                                                                                                                                                     
   ≥80                                                                           1488             162                        35.8              27.2   37.0   1326   41.2   23.0   35.8
   60--79                                                                        4365             617                        41.0              33.4   25.6   3748   59.0   25.6   15.4
   \<60                                                                          1638             216                        54.6              36.6   8.8    1422   66.0   30.8   3.2
  Sex                                                                                                                                                                            
   Female                                                                        3451             531                        49.8              30.0   20.3   3509   59.1   25.4   15.5
   Male                                                                          4040             464                        37.3              35.8   26.9   2987   55.0   27.0   18.0
  Post-observation eGFR[^a^](#tblfn3){ref-type="table-fn"} (mL/min/1.73 m^2^)                                                                                                    
   \<30                                                                          3015             473                        25.6              51.2   23.2   2542   31.9   47.7   20.4
   30--44                                                                        2812             357                        55.2              18.2   26.6   2455   66.3   15.4   18.2
   45--59                                                                        1057             109                        68.8              12.8   18.3   948    81.4   7.9    10.7
   ≥60                                                                           607              56                         64.3              14.3   21.4   551    88.2   7.1    4.7
  Post-observation proteinuria^a^                                                                                                                                                
   Severe                                                                        1468             233                        18.0              62.7   19.3   1235   24.3   57.1   18.6
   Moderate                                                                      1824             277                        34.2              29.6   36.1   1547   44.7   25.1   30.3
   None/mild                                                                     1566             197                        41.1              22.3   36.5   1369   63.7   12.9   23.4
   Not tested                                                                    2633             288                        73.3              19.8   6.9    2345   78.2   18.6   3.2
  Systolic blood pressure (mmHg)                                                                                                                                                 
   ≥160                                                                          911              134                        35.8              41.8   22.4   777    48.3   36.8   14.9
   120--160                                                                      3603             487                        40.2              41.7   18.1   3116   53.7   31.6   14.7
   \<120                                                                         1235             177                        53.1              20.9   26.0   1058   58.4   23.9   17.7
   Not recorded                                                                  1742             197                        46.2              16.8   37.1   1545   66.7   11.8   21.6
  Diastolic blood pressure (mmHg)                                                                                                                                                
   ≥100                                                                          148              24                         37.5              54.2   8.3    124    58.1   32.3   9.7
   60--100                                                                       5014             687                        43.7              36.7   19.7   4327   54.7   30.6   14.7
   \<60                                                                          587              87                         33.3              35.6   31.0   500    45.4   31.6   23.0
   Not recorded                                                                  1742             197                        46.2              16.8   37.1   1545   66.7   11.8   21.6
  Diabetes mellitus                                                                                                                                                              
   Yes                                                                           4511             707                        40.7              35.4   23.9   3804   52.7   30.8   16.5
   No                                                                            2980             288                        48.9              27.4   23.6   2692   62.8   19.9   17.3
  Primary renal diagnosis                                                                                                                                                        
   Diabetes mellitus                                                             1220             207                        34.8              50.2   15.0   1013   45.3   43.4   11.3
   Glomerulonephritis                                                            368              44                         25.0              61.4   13.6   324    50.3   46.0   3.7
   Interstitial/intrinsic renal                                                  699              101                        53.5              29.7   16.8   598    60.9   28.8   10.4
   Multisystem disorder                                                          430              67                         37.3              38.8   23.9   363    59.2   20.4   20.4
   Polycystic kidney disease                                                     159               7                         42.9              57.1   0.0    152    46.7   52.6   0.7
   Vascular/hypertension                                                         1636             225                        49.3              25.3   25.3   1411   57.3   27.6   15.1
   Uncertain aetiology                                                           1059             134                        44.0              29.1   26.9   925    63.3   20.5   16.1
   Not recorded                                                                  1920             210                        44.8              20.0   35.2   1710   60.2   12.3   27.4
  Year of first follow-up                                                                                                                                                        
   2003--06                                                                      3139             440                        44.5              32.3   23.1   2699   58.7   25.4   15.9
   2007--09                                                                      4352             555                        42.0              33.7   24.3   3797   55.6   26.9   17.5

All people in this analysis were observed for 2** **years for the development of AKI. Outcomes refer to CKD stage 5 and death over the subsequent 5** **years thereafter.

Refers to the last measurement from the 2-year observation period.

Cumulative rates of kidney failure and the competing event of death
-------------------------------------------------------------------

[Figure 2](#gfy294-F2){ref-type="fig"} and [Supplementary data](#sup1){ref-type="supplementary-material"}, [Figures S2](#sup1){ref-type="supplementary-material"} and [S3](#sup1){ref-type="supplementary-material"} show the cumulative incidences of kidney failure and death without kidney failure in those with and without AKI, stratified by age, eGFR and primary renal diagnosis, respectively. Stratification by age showed an increase in both kidney failure and death after AKI in all age groups ([Figure 2](#gfy294-F2){ref-type="fig"}). Those ≥80 years of age were more likely to die than reach kidney failure, whereas death was uncommon among those \<60 years of age. AKI was also associated with poorer outcomes irrespective of eGFR ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S2](#sup1){ref-type="supplementary-material"}) and renal diagnosis ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S3](#sup1){ref-type="supplementary-material"}), but the occurrence of the competing event of death varied between subgroups.

![Cumulative incidence of kidney failure and death among those with and without AKI grouped by age (years).](gfy294f2){#gfy294-F2}

Independent association between AKI and kidney failure and death
----------------------------------------------------------------

[Table 3](#gfy294-T3){ref-type="table"} describes the independent role of AKI (versus no AKI) in kidney failure and the competing event of death with stepwise adjustment for age, sex, eGFR, proteinuria and primary renal diagnosis. As eGFR has previously been shown to modify the prognosis of AKI \[[@gfy294-B4], [@gfy294-B5], [@gfy294-B27]\], two separate models were built for those with eGFR ≥30 mL/min/1.73 m^2^ and those with eGFR \<30 mL/min/1.73 m^2^. Irrespective of eGFR, AKI was associated with kidney failure in univariable analysis, however, in multivariable analysis the excess risk associated with AKI among those with eGFR \<30 mL/min/1.73 m^2^ could be explained by adjusting for covariates \[HR 1.05 (95% CI 0.91--1.21)\]. By comparison, among those with eGFR ≥30 mL/min/1.73 m^2^, even after adjusting for potential confounders, those with previous AKI remained at an excess risk \[HR 1.35 (95% CI 1.07--1.70)\]. In a sensitivity analysis using a recognized alternative metric of CKD progression (30% eGFR decline or long-term RRT), there was a similar pattern of excess risk for those with AKI and eGFR ≥30 mL/min/1.73 m^2^ ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S2](#sup1){ref-type="supplementary-material"}). In subgroup analyses ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S3--S5](#sup1){ref-type="supplementary-material"}) we found a similar pattern of a large excess risk of death and small excess risk of kidney failure even when our definition of AKI was restricted to a criterion involving small creatinine changes (\>26 µmol/L) within 48 h. Among those with eGFR ≥30 mL/min/1.73 m^2^, the excess kidney failure risk was substantial for the minority of people who had recurrent AKI episodes \[adjusted HR 2.34 (95% CI 1.50--3.66); [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S5](#sup1){ref-type="supplementary-material"}\].

###### 

Independent role of previous AKI in subsequent kidney failure and competing risk of death

  Comparison            Subgroup   Adjusted covariates                               AKI versus no AKI for kidney failure, HR (95% CI)   AKI versus no AKI for death without kidney failure, HR (95% CI)
  ------------------- ------------ ------------------------------------------------- --------------------------------------------------- -----------------------------------------------------------------
  AKI versus no AKI    eGFR \< 30  --                                                1.24 (1.08--1.42)                                   1.34 (1.09--1.65)
  AKI versus no AKI    eGFR \< 30  Age and sex                                       1.23 (1.07--1.42)                                   1.46 (1.19--1.79)
  AKI versus no AKI    eGFR \< 30  Age, sex and eGFR                                 1.10 (0.95--1.26)                                   1.43 (1.17--1.76)
  AKI versus no AKI    eGFR \< 30  Age, sex, eGFR and proteinuria                    1.03 (0.89--1.18)                                   1.43 (1.16--1.76)
  AKI versus no AKI    eGFR \< 30  Age, sex, eGFR, proteinuria and renal diagnosis   1.05 (0.91--1.21)                                   1.43 (1.16--1.75)
  AKI versus no AKI     eGFR ≥30   --                                                1.55 (1.23--1.94)                                   1.90 (1.57--2.30)
  AKI versus no AKI     eGFR ≥30   Age and sex                                       1.55 (1.24--1.95)                                   2.10 (1.73--2.54)
  AKI versus no AKI     eGFR ≥30   Age, sex and eGFR                                 1.43 (1.13--1.79)                                   2.05 (1.69--2.49)
  AKI versus no AKI     eGFR ≥30   Age, sex, eGFR and proteinuria                    1.34 (1.07--1.69)                                   1.87 (1.54--2.27)
  AKI versus no AKI     eGFR ≥30   Age, sex, eGFR, proteinuria and renal diagnosis   1.35 (1.07--1.70)                                   1.89 (1.56--2.30)

Age as a linear term, eGFR^-2^, proteinuria in four KDIGO albuminuria categories of severe, moderate, normal/mild and not tested. AKI represents AKI occurring in a 2-year observation period prior to study follow-up. eGFR and proteinuria status were determined from the last available sample at the end of the 2-year observation period. The outcome of kidney failure represents a composite of long-term RRT or eGFR  \<15 mL/min/1.73 m^2^ sustained for at least 90 days. eGFR given in mL/min/1.73 m^2^.

5 -Year KFRE and refitted models with and without AKI added
-----------------------------------------------------------

[Table 4](#gfy294-T4){ref-type="table"} compares three models for predicting kidney failure among people with eGFR ≥30 mL/min/1.73 m^2^: external validation of the 5-year KFRE, a refitted model using the same variables (age, sex, eGFR and proteinuria) developed using the Fine and Gray technique \[[@gfy294-B19]\] and a second refitted model incorporating AKI as an additional predictor. As shown by the calibration plot ([Figure 3](#gfy294-F3){ref-type="fig"}) and the calibration slope significantly different from 1 ([Table 4](#gfy294-T4){ref-type="table"}), the KFRE was miscalibrated and underpredicted kidney failure in this cohort. For discrimination, respective AUCs were 0.701, 0.715 and 0.716. Using decision curve analysis, the refitted model with AKI was no better than the refitted model without AKI ([Figure 4](#gfy294-F4){ref-type="fig"}). KFRE was inferior to either refitted model or a 'treat all' approach (i.e. clinical follow-up of all people) if used at any risk threshold between 0% and 10%, as suggested in previous studies \[[@gfy294-B11]\]. Fitting a separate model that included recurrent AKI as a predictor also did not greatly alter discrimination (AUC 0.718).

![Calibration plots for the 5-year kidney failure risk equation and a refitted model with AKI as an added predictor. Circles represent the cohort grouped in increasing tenths of predicted probabilities. KFRE underpredicted 5-year kidney failure in this cohort.](gfy294f3){#gfy294-F3}

![Decision curve analysis of 5-year kidney failure risk prediction models for people with eGFR ≥30 mL/min/1.73 m^2^. KFRE was inferior to a 'treat all' approach when the risk threshold was \<10%. AKI added no value as an additional predictor in a refitted model.](gfy294f4){#gfy294-F4}

###### 

Five-year kidney failure risk prediction models for people with eGFR ≥30 mL/min/1.73 m^2^

  Model                                                                                        Equation                                                                  Calibration slope[^a^](#tblfn6){ref-type="table-fn"}   AUC                     P-value for AUC comparison with next most complex model
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------- ---------------------------------------------------------
  Five-year KFRE                1 −0.924\^exp((−0.2201 \* (((age)/10) −7.036)) + (0.2467 \* (sex−0.5642)) − (0.5567 \* ((eGFR/5) −7.222)) + ((0.451 \* (lnACR−5.137))))  0.44 (0.39--0.49)                                      0.701 (0.676--0.725)                             0.02
  Refitted model without AKI                 1 −0.916\^exp((−0.3074 \* ((age−70)/10)) + (−0.1801 \* ((eGFR−30)/5)) + (0.2227 \* sex) + (0.2292 \* lnACR))                1.00 (0.90--1.10)                                      0.715 (0.691--0.739)                             0.16
  Refitted model with AKI            1 -0.918\^exp((−0.307 \* ((age−70)/10)) + (−0.179 \* ((eGFR−30)/5)) + (0.2224 \* sex) + (0.228 \* lnACR) + (0.148 \* AKI2yr))       1.00 (0.90--1.10)                                      0.716 (0.692--0.741)   

AKI2 yr represents AKI occurring in a 2-year observation period prior to study follow-up (1 = AKI, 0 = no AKI). Age (in years), eGFR and proteinuria were determined from the last available sample at the end of the 2-year observation period. Sex = 1 if male and 0 if female. The outcome of kidney failure represents a composite of long-term RRT or eGFR \<15 mL/min/1.73 m^2^ sustained for at least 90 days.

Calibration slope should be expected to be equal to 1 in the development of refitted models (apparent calibration). For external validation of the KFRE, a slope different from 1 indicates miscalibration.

lnACR, natural logarithm of albumin:creatinine ratio (mg/g).

DISCUSSION
==========

This large long-term analysis of a provincial Canadian cohort is the first to predict kidney failure risk after AKI among people already undergoing nephrology clinic follow-up. There are two important messages for nephrologists.

First, small acute creatinine changes of AKI in people already under nephrology care are associated with a small independent increased risk of kidney failure and a large competing risk of death, irrespective of age or renal diagnosis. Incorporating AKI into kidney failure risk prediction models does not improve predictions, but the reason is likely to be because many people with AKI die before kidney failure. Thus, while AKI may not substantially alter kidney failure risk predictions, the use of prediction models in individuals without an appreciation of the full impact of AKI would be simplistic. Thus the notion of 'competing risk of death' needs to be incorporated more overtly into clinical thinking and discussions with patients.

Second, the established KFRE calibrated poorly when used in people with preserved eGFR (≥30 mL/min/1.73 m^2^) under nephrology clinic follow-up, leading to substantially underpredicted risks. A strategy of caring for all would be better than using the KFRE at a threshold of 3% to prioritize people with eGFR ≥30 mL/min/1.73 m^2^ who should continue to receive nephrology care. Reasons for this are unclear, but people with eGFR ≥30 mL/min/1.73 m^2^ who are followed by nephrologists may already be a high-risk group for reasons not completely captured by the KFRE. In keeping with this, AKI did not vary with age in this cohort, even though old age is an established risk factor for AKI (and death). This suggests selective nephrology follow-up of those in the general population who were most likely to develop kidney failure (rather than die). This complexity indicates that caution is needed when nephrologist apply prediction tools to individual people in specific clinical contexts.

This analysis shows that clinicians should understand better the substantial competing risk of death occurring after AKI before kidney failure can develop. That is, AKI may serve as a 'signal' for adverse outcomes, including but not limited to kidney failure. As illustrated in the cumulative incidence plots of this study, this increased mortality is present irrespective of age, eGFR or underlying renal diagnosis. The substantial competing outcomes after AKI should prompt us to consider the numerous reasons, other than simply kidney failure risk, that people with kidney disease may benefit from nephrology care. Nephrology care may include prevention of recurrent acute illness episodes, prevention of CKD complications, optimization of cardiovascular profile, fluid balance and alleviation of symptoms. To date, there remains little evidence describing the value of nephrology care in optimizing cardiovascular risk for those with advanced CKD or preventing AKI due to drugs or contrast. Future work should examine this for the high-risk group identified in this analysis of AKI survivors.

Our analysis also highlights the importance of clinical context when evaluating AKI. Even if there is a similar pattern of increased risk after AKI across numerous studies, absolute risk differs depending on the clinical context. For instance, the AKI definition in this analysis (in a nephrology clinic population) was identical to that used in previous work (in a general population), but in this analysis the risk of renal progression was substantially higher and the risk of mortality was lower \[[@gfy294-B5]\].

Strengths of this analysis include the large sample size, covering an entire province in Canada. The novel focus on those under nephrology care makes the findings particularly relevant for practising nephrologists and multidisciplinary kidney care clinics. The definition of AKI was comprehensive and KDIGO based and modelling included measures of proteinuria that are frequently unavailable in clinical AKI studies \[[@gfy294-B3], [@gfy294-B6], [@gfy294-B28]\]. Moreover, an opportunity for eGFR to return to baseline after AKI (necessary to avoid confusing non-recovery with progression) \[[@gfy294-B5]\] was provided by using post-AKI episode eGFR values in the analysis after the 2-year observation period. The analysis also can be supported by recent population studies showing the effect modification of AKI outcomes by eGFR in the USA and UK \[[@gfy294-B4], [@gfy294-B27]\] and recent work illustrating the potential value of updating risk prediction tools as new information arises \[[@gfy294-B29]\].

The analysis also has limitations. This analysis involves AKI occurring while under nephrology care and does not include episodes of AKI occurring prior to nephrology referral (which may have prompted referral). This may have led to an attenuation of the association between AKI and outcomes of interest. We recognize that clinical nephrology practices in British Columbia may vary from practices in other countries, although our findings are broadly consistent with a methodologically similar study using a UK cohort \[[@gfy294-B5]\]. We also recognize that as the covariates were obtained from routinely collected health data, not all items were complete (e.g. proteinuria). This, however, reflects real-world clinical practice in nephrology clinics in British Columbia, where not all urine samples are sent for quantification, e.g. when bedside urinalysis is normal. This explains why those without a documented measure of proteinuria had the best outcomes. Additional adjustment for a wider range of comorbidities was also not possible, but we note that wider comorbidities are not a component of the KFRE either. Finally, we note that we tested our prediction models in just one cohort, but this is sufficient for the purpose of our study: for evaluating incremental risk with AKI as a predictor, we used the same dataset and variables for two refitted models so that the only difference between the models was the inclusion of the predictor AKI. For evaluating the use of KFRE, we externally validated an equation already studied in numerous population datasets.

In conclusion, a history of AKI based on small creatinine changes (versus no AKI) carries a poorer long-term prognosis for all outcomes among those already under nephrology clinic care, irrespective of the level of kidney function, age and renal diagnosis. People with CKD and AKI have risks beyond simply kidney failure, including cardiovascular events and death. Clinical appreciation of these other risks and targeted research to identify the best strategies to modify risks in high-risk individulas is critical.
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